myeloma

Volume 16 Number 5 (March 1st, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) Gastrointestinal Cancers Symposium (January 25-27, 2008, Orlando) A

Bart Barlogie Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 BART BARLOGIE, University of Arkansas, Little Rock A treatment known as “total therapy

Kenneth Anderson Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 KENNETH ANDERSON, Dana-Farber Cancer Institute, Boston Multiple myeloma may soon be consi

Cora Sternberg REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 CORA STERNBERG, San Camillo and Forlanini Hospital, Rome Satraplatin could pro

Georg Härter REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 GEORG HÄRTER, University Hospital, Ulm For patients with multiple myeloma b

Clifford Hudis Mark Einstein Tony Greco James Berenson Edward Ambinder Breast Cancer: HER2 Still a Useful Target After Trastuzumab Resistance REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 Nov

Robert Mayer Thierry Facon Ibrahim Yakoub-Agha Peter Paschka Robert Mayer of the Dana-Farber Cancer Institute in Boston joins Derek Thorne to discuss the major hematologic malignancy news reported at

George Canellos Carmela Pepe John Goldman Roy Herbst Sandra Horning George Canellos, from the Dana-Farber Cancer Institute in Boston, joins Derek Thorne to talk about the first day’s news at the

Vincent Rajkumar Vincent Rajkumar, Divison of Hematology, Mayo Clinic At a section of the hematology meeting talking about newly diagnosed multiple myeloma and the evolving treatments, Vincent Rajkuma